{
  "actions": [
    {
      "acted_at": "2015-01-20", 
      "committees": [
        "HSIF"
      ], 
      "references": [], 
      "status": "REFERRED", 
      "text": "Referred to the House Committee on Energy and Commerce.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2015-01-23", 
      "in_committee": null, 
      "references": [], 
      "text": "Referred to the Subcommittee on Health.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "hr406-114", 
  "bill_type": "hr", 
  "by_request": false, 
  "committees": [
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF"
    }, 
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF", 
      "subcommittee": "Subcommittee on Health", 
      "subcommittee_id": "14"
    }
  ], 
  "congress": "114", 
  "cosponsors": [], 
  "enacted_as": null, 
  "history": {
    "active": false, 
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2015-01-20", 
  "number": "406", 
  "official_title": "To amend section 505 of the Federal Food, Drug, and Cosmetic Act to provide incentives for the development of new combination drugs.", 
  "popular_title": null, 
  "related_bills": [], 
  "short_title": "Combination Drug Development Incentive Act of 2015", 
  "sponsor": {
    "district": "3", 
    "name": "Chaffetz, Jason", 
    "state": "UT", 
    "thomas_id": "01956", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2015-01-20", 
  "subjects": [
    "Drug safety, medical device, and laboratory regulation", 
    "Health", 
    "Prescription drugs", 
    "Product development and innovation"
  ], 
  "subjects_top_term": "Health", 
  "summary": {
    "as": "Introduced", 
    "date": "2015-01-20", 
    "text": "Combination Drug Development Incentive Act of 2015\n\nThis bill amends the Federal Food, Drug, and Cosmetic Act to provide a five-year marketing exclusivity period to a new drug approved by the Food and Drug Administration that is a novel combination of active ingredients. The application for the combination drug must contain reports of new clinical investigations that are essential to approval and were conducted or sponsored by the applicant. Currently, a new drug that includes an active ingredient that has already been approved is provided a three-year marketing exclusivity period."
  }, 
  "titles": [
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Combination Drug Development Incentive Act of 2015", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "To amend section 505 of the Federal Food, Drug, and Cosmetic Act to provide incentives for the development of new combination drugs.", 
      "type": "official"
    }
  ], 
  "updated_at": "2016-06-25T06:26:37-04:00", 
  "url": "http://thomas.loc.gov/cgi-bin/bdquery/z?d114:HR406:@@@L&summ2=m&"
}